Additional Relevant Details The FDA approved Johnson & Johnson's IMBRUVICA (ibrutinib) for the treatment of CLL based on Phase 3 RESONATE-2 trial showing INBRUVICA "significantly improved progression-free survival and overall response rate".  IMBRUVICA is now approved for use in all lines of CLL therapy,  as opposed to previous initial approvals for specific conditions of patients with CLL.